Genomic Biomarkers Market Size, Share, Growth Report 2032

Genomic Biomarkers Market Insights

Zion Market Research has published a report on the global Genomic Biomarkers Market, estimating its value at USD 5.29 Billion in 2023, with projections indicating that it will reach USD 9.41 Billion by 2032. The market is expected to expand at a compound annual growth rate (CAGR) of 6.62% over the forecast period 2024-2032. The report explores the factors fueling market growth, the hitches that could hamper this expansion, and the opportunities that may arise in the Genomic Biomarkers Market industry. Additionally, it offers a detailed analysis of how these elements will affect market demand dynamics and market performance throughout the forecast period.

Request Free Sample

Market Overview                   

A biomarker is a substance that is introduced into an organism as a means to examine organ function or other aspects of health. A genomic biomarker is in the form of DNA or RNA. Genomic biomarkers are DNA or RNA characteristics, which act as an indicator of normal biologic processes, pathogenic processes, and/or response to therapeutic or other intervention. Genomic biomarkers offer a valuable tool for genetic testing of various disorders that identifies changes in chromosomes, genes, or proteins. The results of a genetic test can confirm or rule out a suspected genetic condition or help determine a person’s chance of developing or passing on a genetic disorder.

The reports includes key developments strategies in the genomic biomarkers market. Various companies are focusing on strategies such as product launches, product approvals and others such as patents and events. For instance, in 2016, Merck Millipore launches MILLIPLEX MAP for human cytokine assays, with Luminex FLEXMAP 3D platform technology.

Biomarkers are usually biological indicators of some biological condition or state and often are measurable. A biomarker is anything that can be used as an indicator of a particular disease state or some other physiological state of an organism. Biomarkers are usually measured to assess normal physiological processes or pharmacological responses to therapeutic intervention. Genomic biomarker could be a measurement of gene expression, gene function, and gene regulation. Genomic biomarkers are used to measure DNA or RNA characteristics, such as single nucleotide polymorphisms, DNA modifications (methylation), short sequence repeat variability, deletions or insertions in the sequences, copy number variations, cytogenic rearrangements such as translocations, duplications, deletions or inversion, RNA expression, RNA processing (splicing, editing), microRNA expression levels etc.

The genomic biomarkers are not only useful for human DNA or RNA expression levels but also can be used for applications in nonclinical and toxicological samples such as viruses, infectious agents, animal samples etc. Various life-threatening diseases such as cardiovascular diseases, cancer, and neurological disorders pose a great potential risk of death, thus early diagnosis and treatment of such disorders using biomarkers as personalized medicine offer advantage over traditional methods of diagnosis and treatment.

Request Free Sample

Growth Factors

Global genomic biomarkers market is primarily driven by growing prevalence of life-threatening diseases such as cancer, cardiovascular diseases and neurological disorders across the globe. Other major driving factors are a need for genomic biomarker-based personalized medicines and their increasing adoption. However, high cost, complex development procedure, and stringent government regulations are the major restraints that may limit the growth of the market. Nonetheless, growing awareness about advantages of genomic biomarkers over conventional methods for diagnosis coupled with a huge investment in genomic biomarkers across the globe is likely to disclose the new avenues for genomic biomarkers market in the near future.

As per World Health Organization, cardiovascular diseases are number one cause of death worldwide. About 17.5 million people died from CVDs in 2015 representing 31% of all global deaths. Also, according to the American Cancer Society, cancer is the second most common cause of death in the U.S. and accounts for nearly 1 of every 4 deaths. As per World Health Organization estimates, worldwide, there were 14 million new cancer cases in 2012 and 8.8 million cancer-related deaths in 2015. Globally, nearly 1 in 6 deaths is due to cancer. Up to 1 billion people, nearly one in six of the world’s population, suffer from neurological disorders. Also, the global burden of these disorders is increasing owing to increasing geriatric population base across the world. Thus, genomic biomarkers market has vast potential in terms of large patient pool and need for personalized medicines.

Increasing prevalence of lifestyle associated life-threatening diseases such as cardiovascular diseases, cancer, neurological disorders across the globe is expected to be the major driver for the global genomic biomarkers market. In addition, need for genomic biomarker-based personalized medicines coupled with increasing awareness and acceptance of personalized medicines among patients is expected to trigger the growth of global genomic biomarkers industry in the coming years. However, high cost and complex development process coupled with stringent government regulations may pose the challenge to genomic biomarkers market. Nevertheless, growing awareness about advantages of personalized medicines coupled with a huge investment in research and development of genomic biomarkers across the globe is expected to act as an opportunity for genomic biomarkers market in near future.

Request Free Sample

Genomic Biomarkers Market: Report Scope

Segment Analysis Preview  

The genomic biomarkers market is segmented on the basis of different indications such as oncology, cardiovascular diseases, neurological diseases and others. Oncology segment holds a maximum share of global genomic biomarkers market. It helps clinicians make important decisions about the diagnosis, disease stage, therapy plan, and prognosis in patients.

End User Analysis Preview

Based on the End User the market of Genomic Biomarkers has been segmented as Hospitals, Diagnostic & Research Laboratories, and others. Diagnostic & Research Laboratories segment gain a major traction in the market. They can also help doctors decide which patients are likely to respond to a given drug (prediction) and at what dosage it might be most effective (pharmacodynamics).

Request Free Sample

Regional Preview

North America is expected to remain the dominant region over the forecast period. Developed healthcare infrastructure, favorable government policies and research grant are expected to boost the market in this region. Europe was the second largest market followed by the Asia Pacific. The Asia Pacific is expected to show fastest growth rate during the forecast period while Latin America market is projected to grow at a moderate rate during the forecast period. Low cost of clinical trials and large population base in the Asia Pacific region, especially India, China, and Japan are the driving factors for the growth of the genomic biomarkers market in this region. The Middle East and Africa are also expected to experience noticeable growth in the years to come.

Key Market Players & Competitive Landscape

The major players operating Genomic Biomarkers market are :

• Thermo Fisher Scientific
• Roche Diagnostics
• Myriad Genetics
• QIAGEN
• Bio-Rad Laboratories
• US Biomarkers Inc.
• Almac Group
• Epigenomics AG among others.

Request Free Sample

 The global Genomic Biomarkers market is segmented as follows:

By Indication

• Oncology
• Cardiovascular diseases
• Neurological diseases
• Others

By End Users    

• Hospitals
• Diagnostic & Research Laboratories
• Others

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa